The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Clinicians’ Guide to Cannabidiol and Hemp Oils
Open accessAbstract
Cannabidiol (CBD) oils are low tetrahydrocannabinol products derived from Cannabis sativa that have become very popular over the past few years. Patients report relief for a variety of conditions, particularly pain, without the intoxicating adverse effects of medical marijuana. In June 2018, the first CBD-based drug, Epidiolex, was approved by the US Food and Drug Administration for treatment of rare, severe epilepsy, further putting the spotlight on CBD and hemp oils. There is a growing body of preclinical and clinical evidence to support use of CBD oils for many conditions, suggesting its potential role as another option for treating challenging chronic pain or opioid addiction. Care must be taken when directing patients toward CBD products because there is little regulation, and studies have found inaccurate labeling of CBD and tetrahydrocannabinol quantities. This article provides an overview of the scientific work on cannabinoids, CBD, and hemp oil and the distinction between marijuana, hemp, and the different components of CBD and hemp oil products. We summarize the current legal status of CBD and hemp oils in the United States and provide a guide to identifying higher-quality products so that clinicians can advise their patients on the safest and most evidence-based formulations. This review is based on a PubMed search using the terms CBD, cannabidiol, hemp oil, and medical marijuana. Articles were screened for relevance, and those with the most up-to-date information were selected for inclusion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
The Essential Medicinal Chemistry of Curcumin
Nelson, K. M., Dahlin, J. L., Bisson, J., Graham, J., Pauli, G. F., & Walters, M. A. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00975 · Cited by 1,956
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabbout, R., Scheffer, I. E., Thiele, E. A., & Wright, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611618 · Cited by 1,711
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.
Russo, E. B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01238.x · Cited by 1,535
The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of Addiction
Kolodny, A., Courtwright, D. T., Hwang, C. S., Kreiner, P., Eadie, J. L., Clark, T. W., & Alexander, G. C. (2015) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-031914-122957 · Cited by 1,388
Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome
Devinsky, O., Patel, A. D., Cross, J. H., Villanueva, V., Wirrell, E. C., Privitera, M., Greenwood, S. M., Roberts, C., Checketts, D., VanLandingham, K. E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714631 · Cited by 1,015
Hempseed as a nutritional resource: An overview
Callaway, J. C. (2004) · Euphytica · doi:10.1007/s10681-004-4811-6 · Cited by 910 · cited 2×
“Conversely, the seeds of the C sativa contain little to no phytocannabinoids, instead being rich in omega-6 and omega-3 essential fatty acids, substantial amounts of g-linolenic acid, and other nutritious antioxidants.(40) Additionally, there are “cannabis oil” products as well, which are oils derived from the marijua…”
BackgroundBeta-caryophyllene is a dietary cannabinoid.
Gertsch, J., Leonti, M., Raduner, S., Racz, I., Chen, J.-Z., Xie, X.-Q., Altmann, K.-H., Karsak, M., & Zimmer, A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803601105 · Cited by 906
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., Miller, I., Flamini, R., Wilfong, A., Filloux, F., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00379-8 · Cited by 900
Iffland, K., & Grotenhermen, F. (2017) · Cannabis & Cannabinoid Research · doi:10.1089/can.2016.0034 · Cited by 645
US epidemiology of cannabis use and associated problems
Hasin, D. S. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.198 · Cited by 578 · cited 1×
“One promising area has been use of the plant Cannabis sativa, both in medical marijuana as well as hemp and cannabidiol (CBD) oils, with some evidence that access to medical marijuana is correlated with a decrease in opioid use, although there has been controversy about the risks and benefits of encouraging poorly reg…”
BackgroundCannabidiol (CBD) and its analogs: a review of their effects on inflammation.
Burstein, S. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.01.059 · Cited by 573
Safety and side effects of cannabidiol, a Cannabis sativa constituent
Machado Bergamaschi, M., Helena Costa Queiroz, R., Waldo Zuardi, A., & Alexandre S. Crippa, J. (2011) · Current Drug Safety · doi:10.2174/157488611798280924 · Cited by 558 · cited 1×
“Safety and Adverse Effects No rigorous safety studies have been done on “full-spectrum” phytocannabinoid oils because these products are relatively new, but the separate ingredients have been examined somewhat, generally with no major adverse effects noted.(87,88) Cannabidiol doses up to 300 mg/d have been used safely…”
MethodCrippa, J. A. S., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L., Martin-Santos, R., Simões, M. V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., et al. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110379283 · Cited by 535
Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy
Geffrey, A. L., Pollack, S. F., Bruno, P. L., & Thiele, E. A. (2015) · Epilepsia · doi:10.1111/epi.13060 · Cited by 496
Campos, A. C., Moreira, F. A., Gomes, F. V., Del Bel, E. A., & Guimarães, F. S. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0389 · Cited by 475
The Pharmacologic and Clinical Effects of Medical Cannabis
Borgelt, L. M., Franson, K. L., Nussbaum, A. M., & Wang, G. S. (2013) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1187 · Cited by 423
Chagas, M. H. N., Zuardi, A. W., Tumas, V., Pena-Pereira, M. A., Sobreira, E. T., Bergamaschi, M. M., dos Santos, A. C., Teixeira, A. L., Hallak, J. E., & Crippa, J. A. S. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114550355 · Cited by 365
Industrial Hemp in North America: Production, Politics and Potential
Cherney, J., & Small, E. (2016) · Agronomy · doi:10.3390/agronomy6040058 · Cited by 328
Bahi, A., Al Mansouri, S., Al Memari, E., Al Ameri, M., Nurulain, S. M., & Ojha, S. (2014) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.06.003 · Cited by 291
Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes
Oláh, A., Tóth, B. I., Borbíró, I., Sugawara, K., Szöllõsi, A. G., Czifra, G., Pál, B., Ambrus, L., Kloepper, J., Camera, E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci64628 · Cited by 268
Chemistry and Analysis of Phytocannabinoids and Other Cannabis Constituents
Brenneisen, R. (2007) · Forensic Science And Medicine · doi:10.1007/978-1-59259-947-9_2 · Cited by 251
Ren, Y., Whittard, J., Higuera-Matas, A., Morris, C. V., & Hurd, Y. L. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4291-09.2009 · Cited by 210
Phytocannabinoids beyond the Cannabis plant – do they exist?
Gertsch, J., Pertwee, R. G., & Di Marzo, V. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00745.x · Cited by 188
Bluett, R. J., Gamble-George, J. C., Hermanson, D. J., Hartley, N. D., Marnett, L. J., & Patel, S. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.53 · Cited by 157
Cannabidiol was ineffective for manic episode of bipolar affective disorder
Zuardi, A., Crippa, J., Dursun, S., Morais, S., Vilela, J., Sanches, R., & Hallak, J. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881108096521 · Cited by 72
Cited by
Crini, G., Lichtfouse, E., Chanet, G., & Morin-Crini, N. (2020) · Environmental Chemistry Letters · doi:10.1007/s10311-020-01029-2 · Cited by 396
Page, R. L., Allen, L. A., Kloner, R. A., Carriker, C. R., Martel, C., Morris, A. A., Piano, M. R., Rana, J. S., Saucedo, J. F., & On behalf of the American Heart Association Clinical Pharmacology Committee and Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; Council on Lifestyle and Cardiometabolic Health; and Council on Quality of Care and Outcomes Research (2020) · Circulation · doi:10.1161/cir.0000000000000883 · Cited by 260
Rupasinghe, H. P. V., Davis, A., Kumar, S. K., Murray, B., & Zheljazkov, V. D. (2020) · Molecules · doi:10.3390/molecules25184078 · Cited by 260
A review investigating the relationship between cannabis use and adolescent cognitive functioning
Cyrus, E., Coudray, M. S., Kiplagat, S., Mariano, Y., Noel, I., Galea, J. T., Hadley, D., Dévieux, J. G., & Wagner, E. (2021) · Current Opinion in Psychology · doi:10.1016/j.copsyc.2020.07.006 · Cited by 66
“None of the states eligible to be included in the review had legalized recreational use, and two of the states (Virginia and Texas) had limited TCH/CBD programs, with the remaining states having policies short of recreational use or comprehensive medical marijuana use programs (see Figure 1) [15].”
Systematics and Botanical Characteristics of Industrial Hemp Cannabis Sativa L
Strzelczyk, M., Lochynska, M., & Chudy, M. (2022) · Journal of Natural Fibers · doi:10.1080/15440478.2021.1889443 · Cited by 35
Metadata
- Authors
- VanDolah, H. J., Bauer, B. A., & Mauck, K. F.
- Venue
- Mayo Clinic Proceedings
- Publisher
- Elsevier BV
- Published
- 2019-09
- Volume
- 94
- Issue
- 9
- Pages
- 1840-1851
- ISSN
- 0025-6196 (ISSN-L)
- OpenAlex
- W2969431333
- Cited by
- 236
- References
- 27
- FWCI
- 18.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.